Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B

Therapeutic Advances in Hematology - Tập 9 Số 11 - Trang 335-346 - 2018
Johnny Mahlangu1
1Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Academic Hospital, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, 7 York Road, Parktown, Johannesburg 2193, South Africa

Tóm tắt

Whilst the global prevalence of haemophilia B is less than that of haemophilia A, rapid and remarkable innovations have been made in the development of haemophilia B therapies in the last decade. The most recent developments are the evolution of extended half-life haemophilia B replacement therapies which are designed to reduce the treatment burden associated with prophylactic infusion of factor IX (FIX) to prevent bleeding in haemophilia B participants. Clinical development programmes have culminated in the completion of three phase III studies on extended half-life (EHL) recombinant FIX (rFIX) products and subsequent approval and registration of these in many countries around the world. Current data from the three EHL rFIX clinical studies indicate that these products have acceptable safety profiles with no allergic reactions, thromboembolic phenomena or neutralizing antibodies when given to previously treated adolescent and adults for the prevention of bleeds, for the treatment of bleeds and in the perisurgical haemostasis use. Studies in previously untreated paediatric participants are currently ongoing. The EHL rFIX products have the potential impact to reduce the treatment burden associated with prophylactic infusion of replacement FIX, to treat and prevent bleeds in participants with haemophilia B and to improve the participant’s health-related quality of life. The impact of EHL rFIX is likely to be modified by current development of other haemophilia B therapy such as antitissue factor pathway inhibitors and haemophilia B gene therapy. In this review, we aim to provide an update on the safety and efficacy data from the three EHL rFIX clinical studies and to consider their roles in the face of novel haemophilia B therapy currently evolving.

Từ khóa


Tài liệu tham khảo

Srivastava A, 2012, Haemophilia, 19

10.1111/hae.12405

10.1160/TH16-05-0398

10.1111/j.1365-2516.2011.02644.x

10.1111/j.1365-2516.2006.01409.x

10.1046/j.1365-2516.2002.00630.x

10.1046/j.1365-2516.2001.00534.x

10.1111/j.1365-2516.2007.01499.x

10.1111/j.1365-2796.1994.tb00815.x

10.1111/j.1365-2516.2008.01912.x

10.1111/hae.12375

10.1002/pbc.24856

10.1160/TH11-03-0193

10.1111/hae.12715

10.1182/blood-2011-07-367003

Powell J, 2013, Br J Haematol, 11, 358

Powell J, 2013, J Thromb Haemost, 11, 240

10.1182/blood-2009-08-239665

10.1016/S0049-3848(09)70157-4

10.1111/bjh.13112

10.1016/S0049-3848(13)70152-X

10.1182/blood-2015-09-669234

10.1007/s40265-016-0679-8

10.1038/nri2155

10.2174/13892002113149990099

10.1111/hae.12902

10.1111/jth.12000

10.1111/hae.12680

10.1016/j.ejps.2016.06.025

10.2165/00063030-200923020-00003

10.1056/NEJMoa1305074

10.1182/blood-2014-05-573055

10.1182/blood-2011-02-335596

10.1007/s40262-013-0129-7

10.1111/hae.13028

Mahlangu J, 2013, J Thromb Haemost, 11, 168

Fogarty P, 2014, Am J Hematol, 89

Young G, 2014, Haematologica, 99, 791, 10.3324/haematol.2013.098657

10.1111/j.1365-2516.2012.02896.x

10.1111/hae.12159

10.1111/hae.12518

10.1160/TH17-03-0166

10.1016/S2352-3026(16)30193-4

10.1111/jth.13360

10.1111/bjh.13112

Wyrwich KW, 2014, Haemophilia, 20, 169

10.1111/hae.12987

10.1111/jth.13649

10.1111/hae.13583

10.1182/blood-2012-05-429688

10.1111/hae.12721

10.1160/TH16-03-0179

Von Mackensen S, 2017, Res Pract Thromb Haemost, 1

10.1016/j.thromres.2016.02.030

10.1111/hae.13041

10.1111/hae.12995

10.1111/hae.13195

10.1111/jth.12864

10.1056/NEJMoa1616569

10.1056/NEJMoa1407309

10.1182/blood-2017-09-804419

10.1182/blood-2015-09-669234

10.1111/jth.13787

10.1111/jth.13359

10.1111/jth.13348

Thông tin
Thông tin xuất bản

Therapeutic Advances in Hematology

Tập 9 Số 11

335-346

Thông tin tác giả